PKN Stock Overview Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. More details
Rewards Risk Analysis PKN passed our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Add noteRevvity, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Revvity Historical stock prices Current Share Price US$108.00 52 Week High US$121.05 52 Week Low US$92.02 Beta 1.03 1 Month Change -10.00% 3 Month Change -1.55% 1 Year Change 7.78% 3 Year Change -32.35% 5 Year Change 34.16% Change since IPO 682.61%
Recent News & Updates
Revvity, Inc., Annual General Meeting, Apr 22, 2025 Feb 27
Revvity, Inc., Annual General Meeting, Apr 22, 2025 Feb 26
Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Jan 31 Revvity, Inc. to Unveils New Phenologic.AI Software At SLAS2025 in San Diego, San Diego
Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024 Jan 16
Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025 Jan 13 See more updates
Revvity, Inc., Annual General Meeting, Apr 22, 2025 Feb 27
Revvity, Inc., Annual General Meeting, Apr 22, 2025 Feb 26
Revvity, Inc. Provides Earnings Guidance for the Fiscal Year 2025 Jan 31 Revvity, Inc. to Unveils New Phenologic.AI Software At SLAS2025 in San Diego, San Diego
Revvity, Inc. Updates Revenue Guidance for the Fourth Quarter of 2024 Jan 16
Revvity, Inc. to Report Fiscal Year 2024 Results on Jan 31, 2025 Jan 13
Revvity, Inc. Announces Fda Clearance for First Automated Free Testosterone Test Jan 10
Now 20% undervalued after recent price drop Jan 04
Third quarter dividend of US$0.07 announced Dec 30
Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells Nov 20
Dividend of US$0.07 announced Nov 10
Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares. Nov 06
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Nov 05
Third quarter 2024 earnings released: EPS: US$0.76 (vs US$0.26 in 3Q 2023) Nov 04 Revvity, Inc. Declares Quarterly Dividend, Payable on February 7, 2025
Upcoming dividend of US$0.07 per share Oct 11
Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 07
Second quarter 2024 earnings released: EPS: US$0.59 (vs US$0.47 in 2Q 2023) Jul 30
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Jul 30
Dividend of US$0.07 announced Jul 29
Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024 Jul 26
Upcoming dividend of US$0.07 per share Jul 12
Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Jul 10
First quarter 2024 earnings released: EPS: US$0.23 (vs US$0.20 in 1Q 2023) Apr 30
Revvity, Inc. Updates Earnings Guidance for the Full Year 2024 Apr 30
Dividend of US$0.07 announced Apr 29
Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024 Apr 27
Revvity Unveils A New Era of Automated Tuberculosis Testing Apr 24
Upcoming dividend of US$0.07 per share Apr 11
Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Apr 05
Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024 Mar 21
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication Mar 20
Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research Mar 15
Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022) Feb 29
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions Feb 13
New minor risk - Earnings quality Feb 03
Revvity Showcases Cutting-Edge Solutions at SLAS2024 Feb 02
Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022) Feb 02
Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024 Feb 01
Dividend of US$0.07 announced Jan 29
Revvity, Inc., Annual General Meeting, Apr 23, 2024 Jan 27 Revvity, Inc. Announces Board Elections, Effective February 1, 2024
Upcoming dividend of US$0.07 per share at 0.3% yield Jan 11
Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024 Jan 10
Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023 Jan 09
Investor sentiment improves as stock rises 15% Dec 21
Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID Nov 29
Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID Nov 28
New major risk - Revenue and earnings growth Nov 01
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Oct 31
Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.55 in 3Q 2022) Oct 31
Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024 Oct 27
Upcoming dividend of US$0.07 per share at 0.3% yield Oct 12
Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023 Oct 10
Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure Sep 27
Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries Sep 06
New minor risk - Earnings quality Aug 02
Revvity, Inc. Provides Earnings Guidance for the Full Year 2023 Aug 02
Second quarter 2023 earnings released: EPS: US$0.47 (vs US$1.33 in 2Q 2022) Aug 02
Revvity Declares Quarterly Dividend, Payable on November 10, 2023 Jul 23
Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 13
Upcoming dividend of US$0.07 per share at 0.2% yield Jul 13
Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research Jun 30
Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development Jun 13
First quarter 2023 earnings released: EPS: US$0.20 (vs US$1.40 in 1Q 2022) May 12 Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.
Upcoming dividend of US$0.07 per share at 0.2% yield Apr 13
Insufficient new directors Apr 02
PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023 Feb 15
Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021) Feb 15
PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023 Jan 27
Now 22% undervalued after recent price drop Jan 26
Upcoming dividend of US$0.07 per share Jan 12 PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023
Now 24% undervalued after recent price drop Jan 07
Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.94 in 3Q 2021) Nov 16
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns Nov 15
Third quarter 2022 earnings released: EPS: US$0.55 (vs US$1.12 in 3Q 2021) Nov 09
PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022 Nov 09
PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023 Oct 27 PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022
Upcoming dividend of US$0.07 per share Oct 13
PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing Sep 27
Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection Sep 23 PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022
Second quarter 2022 earnings released: EPS: US$1.42 (vs US$2.20 in 2Q 2021) Aug 02
New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion. Aug 02 Shareholder Returns PKN DE Life Sciences DE Market 7D -1.3% -2.9% 1.2% 1Y 7.8% -9.1% 15.1%
See full shareholder returns
Return vs Market: PKN underperformed the German Market which returned 16.6% over the past year.
Price Volatility Is PKN's price volatile compared to industry and market? PKN volatility PKN Average Weekly Movement 4.5% Life Sciences Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.6%
Stable Share Price: PKN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PKN's weekly volatility (5%) has been stable over the past year.
About the Company Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Show more Revvity, Inc. Fundamentals Summary How do Revvity's earnings and revenue compare to its market cap? PKN fundamental statistics Market cap €13.30b Earnings (TTM ) €272.12m Revenue (TTM ) €2.65b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PKN income statement (TTM ) Revenue US$2.76b Cost of Revenue US$1.22b Gross Profit US$1.54b Other Expenses US$1.25b Earnings US$283.07m
Last Reported Earnings
Dec 29, 2024
Earnings per share (EPS) 2.36 Gross Margin 55.81% Net Profit Margin 10.27% Debt/Equity Ratio 41.1%
How did PKN perform over the long term?
See historical performance and comparison Dividends
0.3% Current Dividend Yield When do you need to buy PKN by to receive an upcoming dividend? Revvity dividend dates Ex Dividend Date Apr 17 2025 Dividend Pay Date May 09 2025 Days until Ex dividend 48 days Days until Dividend pay date 70 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/27 01:27 End of Day Share Price 2025/02/27 00:00 Earnings 2024/12/29 Annual Earnings 2024/12/29
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Revvity, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Luke Sergott Barclays Charles Butler Barclays
Show 36 more analysts